Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Antitumor effect of everolimus in a patient with type 3 gastric neuroendocrine tumor.

Bariani GM, Carvalheira JB, Riechelmann RP.

Onkologie. 2013;36(9):502-4. doi: 10.1159/000354637. Epub 2013 Aug 16.

PMID:
24051927
2.

Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas.

Bollard J, Couderc C, Blanc M, Poncet G, Lepinasse F, Hervieu V, Gouysse G, Ferraro-Peyret C, Benslama N, Walter T, Scoazec JY, Roche C.

Neuroendocrinology. 2013;97(4):331-40. doi: 10.1159/000347063. Epub 2013 May 22.

PMID:
23343749
3.
4.

Successful everolimus treatment in a patient with advanced pancreatic neuroendocrine tumor who developed everolimus-induced interstitial lung disease on two occasions: a case report.

Nakayama Y, Ikeda M, Kojima M, Goto K, Hara M, Okuyama H, Takahashi H, Ohno I, Shimizu S, Mitsunaga S, Okusaka T.

Chemotherapy. 2013;59(1):74-8. doi: 10.1159/000351103. Epub 2013 Jul 18.

PMID:
23867634
5.

Everolimus for advanced pancreatic neuroendocrine tumors.

Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group.

N Engl J Med. 2011 Feb 10;364(6):514-23. doi: 10.1056/NEJMoa1009290.

6.

Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems.

Flaum N, Valle JW, Mansoor W, McNamara MG.

Future Oncol. 2016 Nov;12(22):2561-2578. doi: 10.2217/fon.16.23. Epub 2016 Jul 14.

PMID:
27412069
7.

Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.

Thompson LA, Kim M, Wenger SD, O'Bryant CL.

Ann Pharmacother. 2012 Sep;46(9):1212-9. doi: 10.1345/aph.1R087. Epub 2012 Sep 4. Review.

PMID:
22947595
8.

Role of everolimus in pancreatic neuroendocrine tumors.

Goldstein R, Meyer T.

Expert Rev Anticancer Ther. 2011 Nov;11(11):1653-65. doi: 10.1586/era.11.145. Epub 2011 Sep 20. Review.

PMID:
21932937
9.

Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.

Chan HY, Grossman AB, Bukowski RM.

Adv Ther. 2010 Aug;27(8):495-511. doi: 10.1007/s12325-010-0045-2. Epub 2010 Jul 8. Review.

PMID:
20623346
10.

Everolimus dramatically improves glycemic control in unresectable metastatic insulinoma: a case report.

Asayama M, Yamada-Murano T, Hara H, Ooki A, Kurosumi M, Yamaguchi K.

Jpn J Clin Oncol. 2014 Feb;44(2):186-90. doi: 10.1093/jjco/hyt193. Epub 2013 Dec 22.

PMID:
24367043
11.

Everolimus Reduces (89)Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors.

van Asselt SJ, Oosting SF, Brouwers AH, Bongaerts AH, de Jong JR, Lub-de Hooge MN, Oude Munnink TH, Fiebrich HB, Sluiter WJ, Links TP, Walenkamp AM, de Vries EG.

J Nucl Med. 2014 Jul;55(7):1087-92. doi: 10.2967/jnumed.113.129056. Epub 2014 May 1.

12.

Neuroendocrine tumors: treatment updates.

Khagi S, Saif MW.

JOP. 2013 Jul 10;14(4):367-71. doi: 10.6092/1590-8577/1657.

13.

Novel agents in gastroenteropancreatic neuroendocrine tumors.

Stevenson R, Libutti SK, Saif MW.

JOP. 2013 Mar 10;14(2):152-4. doi: 10.6092/1590-8577/1470. Review.

14.

Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.

Kamp K, Gumz B, Feelders RA, Kwekkeboom DJ, Kaltsas G, Costa FP, de Herder WW.

Endocr Relat Cancer. 2013 Oct 14;20(6):825-31. doi: 10.1530/ERC-13-0254. Print 2013 Dec.

15.

Pneumocystis jirovecii pneumonia under everolimus in two patients with metastatic pancreatic neuroendocrine tumors.

Carbonnaux M, Molin Y, Souquet PJ, Tantin A, Lombard-Bohas C, Walter T.

Invest New Drugs. 2014 Dec;32(6):1308-10. doi: 10.1007/s10637-014-0150-1. Epub 2014 Aug 14.

PMID:
25119297
16.

Symptomatic Control of Neuroendocrine Tumours with Everolimus.

Bainbridge HE, Larbi E, Middleton G.

Horm Cancer. 2015 Dec;6(5-6):254-9. doi: 10.1007/s12672-015-0233-2. Epub 2015 Aug 6.

PMID:
26245686
17.

Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.

Peng L, Schwarz RE.

Curr Mol Med. 2013 Mar;13(3):333-9. Review.

PMID:
23331005
18.

Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.

Leung R, Lang B, Wong H, Chiu J, Yat WK, Shek T, Cho WY, Yau LC, Yau T.

Anticancer Agents Med Chem. 2013 Mar;13(3):382-8. Review.

PMID:
23092266
19.

Targeted agents in treatment of neuroendocrine tumors of pancreas.

Karampelas IN, Syrigos KN, Saif MW.

JOP. 2014 Jul 28;15(4):351-3. doi: 10.6092/1590-8577/2694. Review.

20.

Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.

Mateo J, Heymach JV, Zurita AJ.

Mol Diagn Ther. 2012 Jun 1;16(3):151-61. doi: 10.2165/11632590-000000000-00000. Review.

Supplemental Content

Support Center